Abstract
Cell-penetrating peptides (CPPs) have become a great potential non-invasive carrier candidate for the delivery of various cell-impermeable therapeutic cargoes such as proteins, polypeptides and nucleic acid. However, the lack of tissue specificity and entrapment in the endocytic vesicles is the primary limitation to the application of these peptides in cargo delivery. Emphasis should be placed on developing novel methods to overcome these barriers. In this review, several current strategies to promote tissue specificity and endosomal escape of CPPs will be described, as well as the comparison of different approaches in efficacy and security. Finally, this review will be attributed to new ideas to improve the tissue specificity and cytosolic availability of CPP-cargoes.
Keywords: CPPs, cell-type specificity, endosomal escape.
Current Pharmaceutical Design
Title:The Cell-Type Specificity and Endosomal Escape of Cell-Penetrating Peptides
Volume: 21 Issue: 10
Author(s): Jing Feng and Liling Tang
Affiliation:
Keywords: CPPs, cell-type specificity, endosomal escape.
Abstract: Cell-penetrating peptides (CPPs) have become a great potential non-invasive carrier candidate for the delivery of various cell-impermeable therapeutic cargoes such as proteins, polypeptides and nucleic acid. However, the lack of tissue specificity and entrapment in the endocytic vesicles is the primary limitation to the application of these peptides in cargo delivery. Emphasis should be placed on developing novel methods to overcome these barriers. In this review, several current strategies to promote tissue specificity and endosomal escape of CPPs will be described, as well as the comparison of different approaches in efficacy and security. Finally, this review will be attributed to new ideas to improve the tissue specificity and cytosolic availability of CPP-cargoes.
Export Options
About this article
Cite this article as:
Feng Jing and Tang Liling, The Cell-Type Specificity and Endosomal Escape of Cell-Penetrating Peptides, Current Pharmaceutical Design 2015; 21 (10) . https://dx.doi.org/10.2174/1381612820666141023155017
DOI https://dx.doi.org/10.2174/1381612820666141023155017 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Reduced-Intensity Transplantation in the Treatment of Haematological Malignancies: Current Status and Future-Prospects
Current Stem Cell Research & Therapy Suppressing Glioblastoma Stem Cell Function by Aldehyde Dehydrogenase Inhibition with Chloramphenicol or Disulfiram as a New Treatment Adjunct: A Hypothesis
Current Stem Cell Research & Therapy Protein Kinases and Associated Pathways in Pluripotent State and Lineage Differentiation
Current Stem Cell Research & Therapy Gastrin: An Acid-Releasing, Proliferative and Immunomodulatory Peptide?
Mini-Reviews in Medicinal Chemistry Novel Therapeutic Agents Against Cancer Stem Cells of Chronic Myeloid Leukemia
Anti-Cancer Agents in Medicinal Chemistry Long Chain n-3 Polyunsaturated Fatty Acids in the Prevention of Allergic and Cardiovascular Disease
Current Pharmaceutical Design The HLA Region and Autoimmune Disease: Associations and Mechanisms of Action
Current Genomics Pathobiology and Prevention of Cancer Chemotherapy-Induced Bone Growth Arrest, Bone Loss, and Osteonecrosis
Current Molecular Medicine Molecular Imaging of Therapeutic Potential of Reporter Probes
Current Drug Targets Potential Disease Targets for Drugs that Disrupt Protein - Protein Interactions of Grb2 and Crk Family Adaptors
Current Pharmaceutical Design Anthraquinones: Analytical Techniques as a Novel Tool to Investigate on the Triggering of Biological Targets
Current Drug Targets Hepatitis C Virus Infection and Antiviral Treatment in Marginal Zone Lymphomas
Current Clinical Pharmacology Editorial [Hot Topic: Novel and Emerging Drugs for Leukemias (Guest Editor: Tadeusz Robak)]
Current Cancer Drug Targets Cytotoxicity and Target Modulation in Pediatric Solid Tumors by the Proteasome Inhibitor Carfilzomib
Current Cancer Drug Targets Development of Novel, Highly Cytotoxic Fusion Constructs Containing Granzyme B: Unique Mechanisms and Functions
Current Pharmaceutical Design The Mechanistic Links Between Proteasome Activity, Aging and Agerelated Diseases
Current Genomics Development and Assessment of Conventional and Targeted Drug Combinations for Use in the Treatment of Aggressive Breast Cancers
Current Cancer Drug Targets Analysis of Four Types of Leukemia Using Gene Ontology Term and Kyoto Encyclopedia of Genes and Genomes Pathway Enrichment Scores
Combinatorial Chemistry & High Throughput Screening SHP-2 Regulates Growth Factor Dependent Vascular Signalling and Function
Mini-Reviews in Medicinal Chemistry HDAC Inhibitors as Novel Anti-Cancer Therapeutics
Recent Patents on Anti-Cancer Drug Discovery